Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Around 90% of breast cancer patients are diagnosed at an early stage and approximately 70% are hormone receptor-positive and HER2-negative (HR+/HER2-). Despite advancements in adjuvant endocrine therapy, 20-30% of early-stage breast cancer patients relapse within the first decade post-surgery. A recent clinically meaningful therapeutic option for these patients has been cyclin-dependent kinases 4/6 inhibitors (CDK4/6 inhibitors). Abemaciclib and ribociclib were assessed in the adjuvant setting, both showing improvement in invasive disease-free survival (IDFS). Abemaciclib has been approved by the FDA and EMA for HR+/HER2- early breast cancer at high risk of disease recurrence and is the first addition to the Slovenian treatment regimen in routine clinical practice. Poor medication adherence can directly affect the effectiveness of treatment for early HR+/HER2- breast cancer. While adherence data in patients treated with aromatase inhibitors are available, the adherence rate in patients with early HR+/HER2- breast cancer taking abemaciclib remains unclear. In this study, investigators hypothesize that patients receiving abemaciclib in combination with aromatase inhibitors will have lower medication adherence and higher discontinuation rates compared to those receiving aromatase inhibitors alone. It is expected that patients with better quality of life, better cognitive functioning, and a more positive attitude toward their therapy will demonstrate higher medication adherence rates. Adherence may also be influenced by additional factors, such as age and prior treatments.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Kobieta
- •Wczesny rak piersi hormonowrażliwy (HR+/HER2-)
- •Aktualnie otrzymuje leczenie inhibitorem aromatazy (letrozol, anastrozol lub eksemestan), z leczeniem lub bez leczenia inhibitorem CDK4/6 (abemaciklib), przez maksymalnie 18 miesięcy
- •Leczenie raka piersi odbywa się w OIL
- •Posiadanie obowiązkowego ubezpieczenia zdrowotnego przez Instytut Zdrowotny Słowenii
- •Rozumie i posługuje się językiem słoweńskim
- •Wyraża zgodę na uczestnictwo w badaniu i podpisuje formularz świadomej zgody
✗ Disqualifies
- •Przerzutowy rak piersi HR+/HER2-
- •Wcześniejsze leczenie raka piersi inhibitorem aromatazy, z leczeniem lub bez leczenia inhibitorem CDK4/6, we wcześniejszych liniach terapii
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 99 Years
- Last updated (source)
- March 6, 2026
- Sex
- Female only
Locations (1)
Institute of Oncology Ljubljana
Ljubljana, Slovenia
Trial contact
Erika Matos, PhD
Cvetka Grašič Kuhar, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.